CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Abstract

BackgroundThe present study aimed to evaluate the short-term efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres Beads loaded with doxorubicin (DOX) in the treatment of Chinese patients with hepatocellular carcinoma (HCC) compared to conventional TACE (cTACE).MethodsA total of 54 patients with HCC treated by TACE from June 2016 to February 2017 were retrospectively analyzed. These included 24 cases in the DEB-TACE group and 30 cases in the cTACE group. The clinical efficacy, tumor recurrence rate, and complications were compared between the two groups. Furthermore, liver function tests and alpha-feto protein levels were compared between the two groups before and at 1 week and 1 month after interventional treatment.ResultsThere were no significant differences in baseline characteristics (p > 0.05). Tumor response rates and disease control rates in the DEB-TACE group were significantly higher than those in the cTACE group at 3 and 6 months after treatment (p < 0.05). Recurrence rates at 6 months were significantly higher for cTACE compared to DEB-TACE (43.3 vs. 16.7%; p = 0.036). At 1 month, the AFP level in the DEB-TACE group was significantly lower than that in the cTACE group (p = 0.008). At the end of follow-up, four cases in the DEB-TACE group and two cases in the cTACE group were treated with salvage surgery after downstaging the disease. Liver function of both groups improved at 1 month. However, alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels in the DEB-TACE group were better than those in the cTACE group (p < 0.05). The incidence of DOX-related complications in the DEB-TACE group was significantly lower than in the cTACE group (p < 0.05).ConclusionThe short-term efficacy of DEB-TACE is better, and the complication rates are lower compared to cTACE in the treatment of Chinese patients with HCC. However, long-term clinical efficacy and survival benefit should be analyzed in future studies.

The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

“…Wu et al . found that DEB‐TACE markedly increased the DCR at 3 and 6 months after the treatment of hepatocellular carcinoma . However, few studies have evaluated the efficacy of DEB‐BACE in patients with lung cancer, although Kennoki et al .…”

“…Conventional transarterial chemoembolization (TACE) often uses emulsions of lipiodol with chemotherapeutic drugs, which do not reside long in the tumor tissues and thus reduce the local antitumor drug concentration, and may cause systemic AEs . Drug‐eluting beads TACE (DEB‐TACE) has recently been used as a novel drug delivery and embolization system with the ability to not only embolize the tumor‐feeding artery, but also be loaded with chemotherapeutic drugs and release them slowly into the local environment . Several clinical studies showed that doxorubicin‐loaded DEB‐TACE resulted in higher local drug concentration and lower rate of systemic toxicity .…”

“…Drug‐eluting beads TACE (DEB‐TACE) has recently been used as a novel drug delivery and embolization system with the ability to not only embolize the tumor‐feeding artery, but also be loaded with chemotherapeutic drugs and release them slowly into the local environment . Several clinical studies showed that doxorubicin‐loaded DEB‐TACE resulted in higher local drug concentration and lower rate of systemic toxicity . CalliSpheres® beads (CB) is the first DEB product in China, and has just been introduced into clinical use in the last two years, mostly in patients with hepatocellular carcinoma .…”

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

“…Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage due to its insidious onset and nonspecific nature of the symptoms. Currently, transarterial chemoembolization (TACE) has been generally considered as a standard therapeutic method for advanced HCC patients (2,3). Currently, drug-eluting bead TACE (DEB-TACE) has been reported to be more effective and less toxic than conventional TACE in clinical practice (4,5).…”

HCC in Cirrhotic and Non-cirrhotic Liver: Timing to Surgery and Outcome - State of the Art

“…Overall, RFA and MWA provide similar results in terms of local control and survival rates [17]. DEB-TACE induces tumor necrosis through intraarterial delivery of microspheres fulfilled with chemotherapic drug that may vary in size and chemotherapic agent to treat different types of HCC [21]. This technique profits from the presence of a singular artery feeding the tumor.…”